UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
May 23, 2018
(Date of Report - date of earliest event reported)
Arbutus Biopharma Corporation
(Exact Name of Registrant as Specified in Its Charter)
|
British Columbia, Canada |
|
001-34949 |
|
98-0597776 |
|
(State or Other Jurisdiction of |
|
(Commission File Number) |
|
(I.R.S. Employer |
|
Incorporation or Organization) |
|
|
|
Identification No.) |
|
100-8900 Glenlyon Parkway |
|
|
|
Burnaby, British Columbia, Canada |
|
V5J 5J8 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
(604) 419-3200
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.07. Submission of Matters to a Vote of Security Holders.
On May 23, 2018, the Corporation held its Annual General Meeting of Shareholders. At the meeting, shareholders voted in favor of all items of business, as indicated below:
Proposal 1. The Corporation’s shareholders voted to elect the following persons to the board of directors of the Corporation, each to serve until the 2019 Annual General Meeting:
|
Nominee |
|
Votes For |
|
% |
|
Votes |
|
% |
|
Broker Non- |
|
|
Vivek Ramaswamy |
|
29,634,977 |
|
99.39 |
|
181,214 |
|
0.61 |
|
14,035,143 |
|
|
Mark J. Murray |
|
27,766,358 |
|
93.13 |
|
2,049,833 |
|
6.87 |
|
14,035,143 |
|
|
Daniel D. Burgess |
|
29,658,412 |
|
99.47 |
|
157,779 |
|
0.53 |
|
14,035,143 |
|
|
Herbert J. Conrad |
|
29,623,549 |
|
99.35 |
|
192,642 |
|
0.65 |
|
14,035,143 |
|
|
Richard C. Henriques |
|
27,890,391 |
|
93.54 |
|
1,925,800 |
|
6.46 |
|
14,035,143 |
|
|
Keith Manchester |
|
29,616,867 |
|
99.33 |
|
199,324 |
|
0.67 |
|
14,035,143 |
|
|
William T. Symonds |
|
27,859,718 |
|
93.44 |
|
1,956,473 |
|
6.56 |
|
14,035,143 |
|
Proposal 2. The Corporation’s shareholders voted to ratify the appointment of KPMG LLP as independent auditor of the Corporation for the fiscal year ended December 31, 2018:
|
Votes For |
|
% |
|
Votes |
|
% |
|
Abstain |
|
% Abstain |
|
|
43,450,216 |
|
99.09 |
|
235,952 |
|
0.54 |
|
165,166 |
|
0.38 |
|
Proposal 3. The Corporation’s shareholders voted on an advisory basis to approve the compensation of the Named Executive Officers as disclosed in the Proxy Statement/Circular:
|
Votes For |
|
% |
|
Votes |
|
% |
|
Abstain |
|
% Abstain |
|
Broker Non- |
|
|
27,701,235 |
|
92.91 |
|
1,867,432 |
|
6.26 |
|
247,523 |
|
0.83 |
|
14,035,144 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 26, 2018
|
|
ARBUTUS BIOPHARMA CORPORATION | |
|
|
| |
|
|
| |
|
|
By: |
/s/Koert VandenEnden |
|
|
Name: |
Koert VandenEnden |
|
|
Title: |
Interim Chief Financial Officer |